- Trials with a EudraCT protocol (110)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
110 result(s) found for: Amyloid Protein.
Displaying page 1 of 6.
EudraCT Number: 2014-001586-27 | Sponsor Protocol Number: SOMCT01-C | Start Date*: 2014-07-25 | |||||||||||
Sponsor Name:SOM Innovation Biotech SL (SOM Biotech) | |||||||||||||
Full Title: Study of SOM0226 in familial amyloid polyneuropathy (FAP) patients and asymptomatic carriers to evaluate protein stabilization activity | |||||||||||||
Medical condition: Patients with familial amyloid polyneuropathy (FAP), asymptomatic carriers and healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003877-40 | Sponsor Protocol Number: ALN-TTR02-006 | Start Date*: 2015-05-11 | ||||||||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Multicenter, Open-Label, Extension Study to Evaluate the Long-term Safety and Efficacy of Patisiran in Patients with Familial Amyloidotic Polyneuropathy Who Have Completed a Prior Clinical Study ... | ||||||||||||||||||
Medical condition: Transthyretin mediated amyloidosis (ATTR) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) SE (Completed) PT (Ongoing) DE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) CY (Completed) IT (Ongoing) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004627-16 | Sponsor Protocol Number: 70233 | Start Date*: 2020-11-25 | |||||||||||
Sponsor Name:Helsinki University Hospital | |||||||||||||
Full Title: Clinical Validation of Quantitative Flutemetamol PET/CT in Cardiac Amyloidosis | |||||||||||||
Medical condition: Cardiac amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001831-30 | Sponsor Protocol Number: ISIS420915-CS2 | Start Date*: 2013-04-22 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy | |||||||||||||
Medical condition: Familial Amyloid Polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) DE (Completed) IT (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004561-13 | Sponsor Protocol Number: ISIS420915-CS3 | Start Date*: 2014-07-04 | |||||||||||
Sponsor Name:Ionis Pharmaceuticals, Inc | |||||||||||||
Full Title: An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of ISIS 420915 in Patients with Familial Amyloid Polyneuropathy (FAP) | |||||||||||||
Medical condition: Familial Amyloid Polyneuropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) FR (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002987-17 | Sponsor Protocol Number: ALN-TTR02-004 | Start Date*: 2013-11-25 | ||||||||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc | ||||||||||||||||||
Full Title: APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneu... | ||||||||||||||||||
Medical condition: Transthyretin mediated amyloidosis (ATTR) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) ES (Completed) PT (Completed) IT (Completed) DE (Completed) NL (Completed) GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004670-10 | Sponsor Protocol Number: AG10-333 | Start Date*: 2020-07-07 | |||||||||||
Sponsor Name:Eidos Therapeutics, Inc. | |||||||||||||
Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of AG10 in Subjects with Symptomatic Transthyretin Amyloid Polyneuropathy (ATTRibute-PN Trial) | |||||||||||||
Medical condition: Symptomatic Transthyretin Amyloid Polineuropathy (ATTR-PN) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) DE (Prematurely Ended) PT (Prematurely Ended) FR (Completed) BG (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-011535-12 | Sponsor Protocol Number: Fx1A-303 | Start Date*: 2009-08-26 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: Open-Label Safety and Efficacy Evaluation of Fx-1006A in Patients with Transthyretin Amyloidosis | |||||||||||||
Medical condition: Transthyretin Amyloidosis (ATTR) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) FR (Completed) PT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002098-23 | Sponsor Protocol Number: ALN-TTRSC02-002 | Start Date*: 2019-05-09 | ||||||||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis) | ||||||||||||||||||
Medical condition: Hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) PT (Ongoing) GB (GB - no longer in EU/EEA) BG (Ongoing) ES (Ongoing) BE (Ongoing) GR (Ongoing) NL (Ongoing) CY (Ongoing) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000467-24 | Sponsor Protocol Number: ALN-TTR02-002 | Start Date*: 2012-05-08 | ||||||||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients with TTR Amyl... | ||||||||||||||||||
Medical condition: Transthyretin mediated amyloidosis (ATTR) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) PT (Completed) DE (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-001644-65 | Sponsor Protocol Number: ALN-TTR02-003 | Start Date*: 2013-07-19 | ||||||||||||||||
Sponsor Name:Alnylam Pharmaceuticals, Inc. | ||||||||||||||||||
Full Title: A Phase 2, Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTR02 in Patients With Familial Amyloidotic Polyneuropathy Who ... | ||||||||||||||||||
Medical condition: Transthyretin mediated amyloidosis (ATTR) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PT (Completed) SE (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000794-31 | Sponsor Protocol Number: October2011,version5 | Start Date*: 2011-06-15 | |||||||||||
Sponsor Name:Dept. of Pharmacology | |||||||||||||
Full Title: Neurodegenerative Changes in Alzheimer’s Disease: Identifying potential effects of Victoza® on degenerative changes | |||||||||||||
Medical condition: Alzheimer's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005643-22 | Sponsor Protocol Number: AG10-304 | Start Date*: 2022-02-07 | |||||||||||
Sponsor Name:Eidos Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label Extension and Safety Monitoring Study of Acoramidis (AG10) in Participants with Symptomatic Transthyretin Amyloid Cardiomyopathy Who Completed the Phase 3 ATTRibute-CM Trial (AG10-301) | |||||||||||||
Medical condition: Symptomatic Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) IT (Ongoing) ES (Ongoing) IE (Ongoing) NL (Ongoing) GR (Ongoing) CZ (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005384-16 | Sponsor Protocol Number: FLORAMICAR | Start Date*: 2016-04-26 | ||||||||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | ||||||||||||||||||
Full Title: A prospective single-arm, monocentric, phase-II explorative study on evaluation of diagnostic use of the PET tracer (18F)-florbetaben (Neuraceq®) in patient with patient with suspected cardiac amyl... | ||||||||||||||||||
Medical condition: Patients with high clinical suspicion of cardiac amyloidosis | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-002465-35 | Sponsor Protocol Number: B3461028 | Start Date*: 2014-04-07 | |||||||||||
Sponsor Name:FoldRx Pharmaceuticals, a Pfizer Company | |||||||||||||
Full Title: A multicentre, international, phase 3, double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of daily oral dosing of tafamidis meglumine (PF-06291826)... | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) ES (Completed) DE (Completed) SE (Completed) CZ (Completed) NL (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-013030-25 | Sponsor Protocol Number: GE-067-007 | Start Date*: 2010-05-12 | |||||||||||
Sponsor Name:GE Healthcare Ltd. and its Affiliates | |||||||||||||
Full Title: A Principal Open-Label Study to Compare the Brain Uptake of [18F]flutemetamol with Brain Amyloid Levels Determined Post-Mortem | |||||||||||||
Medical condition: The subjects have a short life expectancy. GE-067-007 will determine the level of association between brain uptake of (18F)flutemetamol and brain amyloid levels. Assessments will be based on analy... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000686-40 | Sponsor Protocol Number: pulsar | Start Date*: 2023-05-04 | |||||||||||
Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO | |||||||||||||
Full Title: Prospective, monocentric, exploratory phase II study for the evaluation of the diagnostic use of the tracer PET (18F) -Flutemetamol (Vizamyl®) in patients with cardiac amyloidosis | |||||||||||||
Medical condition: cardiac amyloidosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000868-42 | Sponsor Protocol Number: B3461045 | Start Date*: 2016-09-26 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYR... | |||||||||||||
Medical condition: Transthyretin amyloid cardiomyopathy (TTR-CM) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) CZ (Completed) DE (Completed) SE (Completed) NL (Completed) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005542-38 | Sponsor Protocol Number: MK-8931-019 | Start Date*: 2014-03-17 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., | |||||||||||||
Full Title: A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 (SCH 900931) in Subjects with Amnestic Mild Cognitive Impairment... | |||||||||||||
Medical condition: prodromal Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DE (Completed) GB (Prematurely Ended) FI (Completed) NL (Prematurely Ended) BE (Completed) HU (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004776-56 | Sponsor Protocol Number: AT1-2017 | Start Date*: 2019-03-06 |
Sponsor Name:Arctic Therapeutics ehf | ||
Full Title: Phase IIa Biomarker Study to Evaluate the Efficacy, Safety and Tolerability of AT-1 in Patients with Hereditary Cystatin C Amyloid Angiopathy (HCCAA) - the AT1-HCCAA study | ||
Medical condition: Hereditary Cystatin C Amyloid Angiopathy (HCCAA) | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: IS (Prematurely Ended) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.